US LNG exports surge but will buyers in China turn up?
FOSTER CITY, Calif. - Geron Corporation (NASDAQ:GERN), a biopharmaceutical company focused on blood cancer treatments with a market capitalization of $949 million, has revealed new data on its drug RYTELO® at major oncology conferences. According to InvestingPro analysis, the company maintains a strong financial position with more cash than debt on its balance sheet, though it’s currently trading below its Fair Value. The presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress highlighted RYTELO’s efficacy in lower-risk myelodysplastic syndromes (LR-MDS) and its progress in myelofibrosis trials.
RYTELO, a telomerase inhibitor, has shown clinical benefits for LR-MDS patients, irrespective of their ring sideroblast status, baseline serum erythropoietin levels, or previous treatments. Post-hoc analyses from the IMerge trial suggest that the drug can extend the period patients remain free from blood transfusions, a key treatment goal for LR-MDS. Additionally, certain patients treated with RYTELO reported sustained quality-of-life improvements.
Ongoing trials, IMpactMF and IMproveMF, are exploring the potential of imetelstat, the active ingredient in RYTELO, for treating myelofibrosis. Preliminary data from the IMproveMF trial indicates that imetelstat, in combination with ruxolitinib, is well-tolerated and may offer benefits for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis.
The Phase 3 IMpactMF trial has reached approximately 80% of its enrollment target as of February 2025, focusing on relapsed/refractory myelofibrosis patients. While the company’s revenue grew significantly over the last twelve months to $116.3 million, InvestingPro data shows the company is still working toward profitability, with analysts forecasting continued growth in the current year.
Dr. Faye Feller, Geron’s Chief Medical Officer, expressed confidence in telomerase inhibition as a transformative clinical strategy. She underscored RYTELO’s potential to meet critical needs in LR-MDS treatment, reflecting the company’s commitment to exploring the full potential of this therapeutic approach.
RYTELO is approved in the United States for certain adult LR-MDS patients with transfusion-dependent anemia and in the European Union as a monotherapy for similar conditions. It functions by inhibiting the enzyme telomerase, which is often overexpressed in malignant bone marrow cells, allowing uncontrolled cell division.
This report is based on a press release statement from Geron Corporation. Despite recent market volatility resulting in a 64% decline over the past six months, the stock has shown resilience with an 11% gain in the past week. For deeper insights into GERN’s financial health and growth prospects, including exclusive ProTips and comprehensive valuation metrics, visit InvestingPro, where you’ll find detailed analysis in our Pro Research Report, available for over 1,400 US stocks.
In other recent news, Geron Corporation reported its first-quarter 2025 earnings, meeting analysts’ expectations with an earnings per share (EPS) of -0.03. However, the company fell short on revenue, reporting $39.6 million against the anticipated $50.46 million. This revenue miss has sparked concerns among investors. Despite this, demand for RYTELLO, Geron’s new treatment, grew by 10% in April, indicating some positive momentum. Additionally, stockholders approved amendments to Geron’s equity incentive and employee stock purchase plans, increasing the share reserve significantly. These amendments were part of key proposals voted on during the company’s annual stockholders meeting. Meanwhile, Geron is focusing on the commercialization of RYTELLO, with plans to expand its commercial field team to enhance market penetration. The company also announced that Ernst & Young LLP will continue as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.